jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) has filed lawsuits against four telehealth platforms that the pharma giant alleges are selling compounded versions of its blockbuster GLP-1/GIP receptor agonist tirzepatide that are not FDA-approved, are untested, and could be dangerous to consumers.
The complaints